Literature DB >> 10947156

Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia.

L Liaudet1, A Szabó, F G Soriano, B Zingarelli, C Szabó, A L Salzman.   

Abstract

Peroxynitrite-mediated DNA strand breaks trigger poly (ADP-ribose) synthetase (PARS) activation, resulting in intracellular energetic failure and organ dysfunction. We investigated the role of PARS activation on the inflammatory and functional response of the intestine to mesenteric ischemia-reperfusion injury. Anesthetized rats exposed to 15 min occlusion of the superior mesenteric artery showed an increased mucosal PARS activity (ex vivo incorporation of radiolabelled NAD+ in gut mucosal scrapings) as soon as 10 min after reperfusion. During the first 30 min of reperfusion, significant mucosal damage developed, as well as mucosal hyperpermeability to a 4000 MW fluorescent dextran (FD4). These alterations were significantly reduced by treatment with the NO synthase inhibitor L-NMA, which blocks the production of peroxynitrite, as well as with the PARS inhibitors 3-aminobenzamide and nicotinamide, whereas they were markedly enhanced by the glutathione depletor L-buthionine-(S,R)-sulfoximine. Also, PARS inhibition significantly reduced ileal neutrophil infiltration (myeloperoxidase activity) at 3 h reperfusion. In a second set of experiments, the effects of 15 or 30 min ischemia followed by 3 h reperfusion were evaluated in PARS knockout and wild-type mice. Significant protection against histological damage, neutrophil infiltration, and mucosal barrier failure (evaluated by the mucosal-to-serosal FD4 clearance of everted ileal sacs incubated ex vivo) was noted in PARS knockout mice, who also showed reduced alterations in remote organs, as shown by lesser lipid peroxidation (malondialdehyde formation) and neutrophil infiltration in the lung and liver. In conclusion, PARS plays a crucial role in mediating intestinal injury and dysfunction in the early and late phases of mesenteric reperfusion. Pharmacological inhibition of PARS may be a novel approach to protect tissues from reperfusion-related damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947156     DOI: 10.1097/00024382-200014020-00010

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  18 in total

1.  Hypoxia-inducible factor plays a gut-injurious role in intestinal ischemia reperfusion injury.

Authors:  Kolenkode B Kannan; Iriana Colorado; Diego Reino; David Palange; Qi Lu; Xiaofa Qin; Billy Abungu; Anthony Watkins; Francis J Caputo; Da-Zhong Xu; Gregg L Semenza; Edwin A Deitch; Rena Feinman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-23       Impact factor: 4.052

2.  Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A P Caputi; K Aston; D P Riley; D Salvemini
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Pathophysiological roles of peroxynitrite in circulatory shock.

Authors:  Csaba Szabó; Katalin Módis
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

4.  HIF-1 mediates pathogenic inflammatory responses to intestinal ischemia-reperfusion injury.

Authors:  Rena Feinman; Edwin A Deitch; Anthony C Watkins; Billy Abungu; Iriana Colorado; Kolenkode B Kannan; Sharvil U Sheth; Francis J Caputo; Qi Lu; Madhuri Ramanathan; Shirhan Attan; Chirag D Badami; Danielle Doucet; Dimitrios Barlos; Marta Bosch-Marce; Gregg L Semenza; Da-Zhong Xu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-05       Impact factor: 4.052

5.  Direct peritoneal resuscitation from hemorrhagic shock: effect of time delay in therapy initiation.

Authors:  El Rasheid Zakaria; R Neal Garrison; Touichi Kawabe; Patrick D Harris
Journal:  J Trauma       Date:  2005-03

6.  Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase.

Authors:  L Liaudet; F G Soriano; E Szabó; L Virág; J G Mabley; A L Salzman; C Szabo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

7.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

8.  Gut hyperpermiability after ischemia and reperfusion: attenuation with adrenomedullin and its binding protein treatment.

Authors:  Shinya Higuchi; Rongqian Wu; Mian Zhou; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.